Vascular Cures Boosts Board Strength with UC Davis Vice Chancellor and UnitedHealthcare Executive

julie_freischlagVascular Cures, the only national non-profit focused on transforming research and health for diseases outside the heart, announced the addition of two new board members: Julie Freischlag, MD, Vice Chancellor for Human Health Sciences and Dean of the School of Medicine at UC Davis and Lori C. McDougal, a former member of the UnitedHealthcare (UHG) executive leadership team and CEO of the UHG Military and Veterans business segment.
“Dr. Freischlag and Ms. McDougal bring unique perspectives on the challenges of health care in the 21st century. Their perspectives will help guide our strategic initiatives to empower patients while supporting life-saving research,” said Wendy Hitchcock, Vascular Cures CEO. “As a leader of a major academic health system, Dr. Freischlag knows the opportunities to improve patient outcomes through research, technology and innovative care. And as a senior executive at one of the country’s largest health insurers, Ms. McDougal has been at the forefront of developing new models for care delivery to improve health while addressing skyrocketing costs. We are honored to have them join the Vascular Cures’ leadership team.”

lori_mcdougalMs. McDougal is an independent Board member who has engineered transformational market expansion across government, commercial and international sectors. Her industry thought leadership helps to align health policy, academic research and market trends to create clarity of insight. As previous CEO and founder of UnitedHealthcare Military and Veterans, she created a $4.1 billion dollar division serving more than 2.9 million military beneficiaries. Dr. Freischlag oversees UC Davis Health System’s academic, research and clinical programs including the Schools of Medicine and Nursing, the 1,000-member physician practice group, and UC Davis Medical Center. She is particularly excited about Vascular Cures’ new digital health engagement platform, Project Voice, as it is the first unified platform for patient-engagement and patient-reported outcomes research for vascular disease. Her experience as a vascular surgeon showed her the need for such a program to catalyze greater collaboration between patients, researchers, providers and industry. Read the press release here.

Post a comment